Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France
Table 7
Response rates by first-line regimen and histologic category, overall.
Characteristic
Best response according to RECISTa
Complete response
Partial response
Stable disease
No response/disease progression
First-line regimen, n (%)
Doxorubicin ()
5 (1.5)
120 (36.4)
115 (34.9)
87 (26.4)
Doxorubicin + ifosfamideb ()
14 (9.2)
71 (46.4)
40 (26.1)
28 (18.3)
Docetaxel + gemcitabine ()
3 (4.3)
35 (50.0)
18 (25.7)
14 (20.0)
Paclitaxel ()
5 (14.7)
9 (26.5)
6 (17.7)
13 (38.2)
Ifosfamideb ()
0
7 (21.2)
14 (42.4)
11 (33.3)
All other regimens ()
18 (9.6)
71 (38.0)
54 (28.9)
43 (23.0)
Histologic categorycn (%)
Leiomyosarcoma ()
15 (6.6)
104 (45.4)
66 (28.8)
44 (19.2)
Others/NOS ()
7 (3.8)
70 (38.3)
52 (28.4)
52 (28.4)
Fibroblastic/myofibroblastic sarcoma ()
5 (6.4)
24 (30.8)
34 (43.6)
15 (19.2)
Liposarcoma ()
4 (3.8)
34 (32.4)
32 (30.5)
32 (30.5)
Vascular sarcoma ()
8 (10.1)
25 (31.7)
22 (27.9)
23 (29.1)
Rhabdomyosarcoma ()
5 (5.8)
41 (47.7)
22 (25.6)
18 (20.9)
Synovial sarcoma ()
1 (2.1)
15 (31.9)
19 (40.4)
12 (25.5)
NOS: not otherwise specified; RECIST: Response Evaluation Criteria in Solid Tumors; aamong patients with known response; bmesna was always coadministered with ifosfamide; cresponse rates are for first-line regimens administered in each histologic category.
